Atea Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Atea Pharmaceuticals

10/05/2025 24:04

Atea Pharmaceuticals Inc AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 41 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.00​, above​ its last closing price of $2.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.38
-0.37
-0.40
Missed
-8.1
Sep. 30 2024
-0.46
-0.49
-0.37
Beat
25.3
Jun. 30 2024
-0.76
-0.76
-0.48
Beat
37.3​
Mar. 31 2024
-0.63
-0.61
-0.75
Missed
-23.6
​​Dec. 31 2023
-0.49
-0.50
-0.47
Beat
5.4
Sep. 30 2023
-0.45
-0.48
-0.40
Beat
16.1​
Jun. 30 2023
-0.45
-0.47
-0.34
Beat
27.7
Mar. 31 2023
-0.47
-0.48
-0.43
Beat
9.9

This summary was machine generated May 9 at 23:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)